Success Of Bristol’s Daklinza In Europe May Be Tied To Fate Of Sovaldi

The close relationship between Bristol-Myers Squibb’s Daklinza and Gilead’s Sovaldi for HCV means the triumph or failure of the latter drug in HTA processes might determine the future of both in Europe.